Cidara Therapeutics (Nasdaq: CDTX) presented a late-breaking abstract on CD388 at the 10th ESWI Influenza Conference (Oct 20-23, 2025) in Valencia, Spain.The presentation linked preclinical mouse data to clinical outcomes from the Phase 2b NAVIGATE study, reporting that a single CD388 dose protected mice against 12 seasonal and multiple pandemic influenza subtypes and that plasma concentrations at infection time conferred complete protection. Phase 2b results reportedly showed statistically significant prevention efficacy across all dose groups, with lower drug concentrations correlating with higher infection rates. Exposure-response modeling indicated a clear concentration-response alignment between mouse efficacious exposures and Phase 2b prevention efficacy. Cidara said these findings support its ongoing Phase 3 ANCHOR trial targeting vulnerable populations.

To support early career scientists in the field of respiratory virus infections, ESWI has launched an award recognizing the most promising body of work. Open to early career scientists worldwide, the ...